A course is not a subscription
Hydroquinone, topical steroids and oral antibiotics all require a stop. A subscription's default behaviour is that it continues. One company in the register has built the stop into the product.
The most consistent structural problem in this category is not a formulation fault. It is that drugs which are conventionally time-limited are sold through a billing arrangement whose default is continuation.
Hydroquinone is the clearest example because the stop is not controversial. Prolonged use carries a risk of exogenous ochronosis, the paradoxical blue-black darkening that is difficult to treat and sometimes permanent, and every clinical source treats the drug as a course. The companies selling it agree — in their support material.
Read that table carefully, because two different failures are in it. Dermatica states a correct cycle twice, in two places, and sells its largest discount against twice the longer figure. Obagi publishes a genuine stopping rule — and it is a futility rule. It tells you when to give up if the drug is not working. It says nothing about when to stop if it is, which is the question ochronosis actually poses.
The steroid version
The same shape recurs with topical corticosteroids, where the clock is shorter and better defined. Dermatica's melasma pool reproduces the Kligman triple combination — hydroquinone, tretinoin and fluocinolone acetonide — which is the composition of the only melasma product the FDA has approved. That product is licensed for up to eight weeks, and the limit is set by the steroid.
The page states no duration limit. It promises results within twelve weeks, and the cheapest tier at checkout is twelve months paid upfront. The word steroid does not appear on it.
Eight weeks is not a footnote. It is the difference between the best-evidenced melasma treatment there is and a topical steroid running indefinitely on a face.
A current formula-transition example
Agency now describes clinician-directed transitions between hydroquinone and non-hydroquinone Dark Spot Rx formulas. The current public page does not establish a fixed calendar for every patient. Ask for the prescribed ingredients, planned review date and transition instructions in writing.
The earlier Agency comparison described hydrocortisone as confined to support material. Its current page lists it among candidate ingredients. That correction does not establish how long an individual patient should use it: the assigned prescription and clinician's course plan still need to answer that question.
The only product here that cycles itself off and ships the replacement unasked.
The Tri-Luma composition, licensed for eight weeks, sold with no duration limit and a twelve-month prepay.
Hydroquinone 4% against the company's own three-to-four-month cycling guidance.
A futility rule where a cumulative limit was needed, and no mention of ochronosis.
Hydroquinone 12% on the largest surface area on the body, billed monthly.
A four-month membership for a course the same page says runs eighteen to twenty-four.
What we look for now
- A stated duration on the page that takes the payment, not in a help-centre article.
- A cumulative limit where the risk is cumulative, distinct from a futility rule.
- A step-down formula that exists, so stopping is a product rather than an act of will.
- Discount structures that do not reward committing past the drug's own clock.
Follow-up, dispensing and billing have separate clocks
A patient may have a finite messaging window, a review date, a number of authorized refills and an automatic shipment on different dates. A recurring charge cannot resolve whether a particular ingredient should continue. Ask the clinician and dispenser how the next order will reflect a changed treatment plan.
Four dates to record before the first refill.
A current formula-transition example.
An antibiotic combination with its own review and handling questions.
Sources
- S-01Agency — Dark Spot Rx
Current $110 price, 18 g / 60-day supply, possible hydroquinone and non-hydroquinone formulas, and clinician-directed transitions. Checked 13 September 2026.
- S-02DailyMed — CABTREO prescribing information
Label revised March 2025: exact strengths, acne indication, two vehicle-controlled trials, contraindications and ten-week dispensing expiration. Checked 13 September 2026.